Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies
Status:
Withdrawn
Trial end date:
2011-08-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate if a drug commonly used to treat excessive day-time
sleepiness, called armodafinil (Nuvigil), is also effective in improving the impairment in
the attention commonly reported by patients with more advanced Parkinson's disease (PD) and
Lewy body disease (LBD).